DEVICES IN HEART FAILURE

Disclosure(s):

William T. Abraham, MD: Abbott: Consulting Fees (e.g., advisory boards) (Ongoing); AquaPass: Consulting Fees (e.g., advisory boards) (Ongoing); Bioventrix: Consulting Fees (e.g., advisory boards) (Ongoing); Cardiac Dimensions: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-privately held company (Ongoing); Cordio Medical: Consulting Fees (e.g., advisory boards) (Ongoing); CVRx: Consulting Fees (e.g., advisory boards) (Ongoing); Impulse Dynamics: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Innoventric: Consulting Fees (e.g., advisory boards) (Ongoing); JNJ V-Wave: Consulting Fees (e.g., advisory boards) (Ongoing); SCPharmaceuticals: Consulting Fees (e.g., advisory boards) (Terminated, October 31, 2025), Stock-publicly held company (excluding mutual/index funds) (Terminated, October 31, 2025); Sensible Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Vectorious Medtech: Consulting Fees (e.g., advisory boards) (Ongoing); WhiteSwell: Consulting Fees (e.g., advisory boards) (Ongoing); Zoll Respicardia: Consulting Fees (e.g., advisory boards) (Ongoing)

Phillip Adamson, MD: Abbott Labs: Stock-publicly held company (excluding mutual/index funds) (Ongoing); CVRx: Employee (Ongoing), Stock-publicly held company (excluding mutual/index funds) (Ongoing)

Phillip H. Lam, MD: No financial relationships to disclose